Senopsys and Patheon (PTI.TO) Collaborate to Develop Palatable Drug Products
6/19/2007 1:00:59 PM
SAUGUS, Mass.--(BUSINESS WIRE)--Senopsys LLC, a specialty pharmaceutical services company, announced today that it has signed a collaboration agreement with Patheon Inc. (TSX:PTI), a leading global provider of drug development and manufacturing services, to accelerate the development of palatable drug products. Through this collaboration, Senopsys clients will have access to prototype drug formulations manufactured by Patheon and Patheon will be able to offer its clients taste assessment and optimization services.
comments powered by